ARMP Armata Pharmaceuticals Quick Ratio

Armata Pharmaceuticals (ARMP) is facing a liquidity shortage and the depletion of reserves, leaving the company dependent on capital injections from its primary owners. The business focuses on developing phage-based treatments for the hospital sector, targeting the combat of resistant pulmonary pathogens. This daily price chart on GURU.Markets, where the indicator stands at 0.11, complements data regarding the costly logistics of maintaining temperature-controlled environments during drug transport.

The operational resilience of Armata Pharmaceuticals (ARMP) depends directly on its ability to instantaneously cover obligations without liquidating inventories. This metric measures net solvency by summing only cash and accounts receivable. For a company whose survival is tied to the FDA certification of bacteriophages, this serves as a critical liquidity filter. By analyzing the critical solvency ratio, an investor can timely diagnose the risk of a cash crunch.